Companies › Biomea Fusion
2 active drug programs in 3 registered trials: 2 Phase 2, 1 Phase 1; Metabolic and endocrine; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| icovamenib 100 mg Menin inhibitor | MEN1 | Phase 2 | Type 2 Diabetes | Mar 2027 |
| BMF-650 | – | Phase 1 | Obesity | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07223216 | BMF-650 | Phase 1 | Obesity | Metabolic and endocrine | Aug 2026 |
| NCT07502495 | icovamenib 100 mg | Phase 2 | Type 2 Diabetes | Metabolic and endocrine | Mar 2027 |
| NCT07502508 | icovamenib 100 mg | Phase 2 | Type 2 Diabetes | Metabolic and endocrine | Jun 2027 |
Cash of $35m on 2026-06-30; operating cash outflow about $44m a year; runway about 10 months at that burn, to Apr 2027; 1 of 2 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Kura Oncology Syndax Pharmaceuticals Johnson & Johnson (Janssen) Sumitomo Pharma America
Yarrow Bioscience JCR Pharmaceuticals Amorphical ERX Pharmaceuticals Hyundai Pharm
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.